Tokai Pharmaceuticals Announces Pricing Of Initial Public Offering

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tokai Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven diseases, today announced the pricing of its initial public offering of 6,480,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by Tokai. In addition, Tokai has granted the underwriters a 30-day option to purchase from the company, at the public offering price, less underwriting discounts and commissions, up to an additional 972,000 shares of common stock. Tokai’s common stock is expected to begin trading on The NASDAQ Global Market on Wednesday, September 17, 2014 under the ticker symbol “TKAI.”

Help employers find you! Check out all the jobs and post your resume.